BioCryst reports FY2024 ORLADEYO net revenue $437M (+34% YoY), guides FY2025 $515-535M

BIOCRYST PHARMACEUTICALS INC

2024-FY EPS reported -$0.43 revenue$450,712,000

Preliminary FY2024 ORLADEYO net revenue $437M (+34% YoY); Q4 net revenue $123.5M (+36% YoY).
Total FY2024 revenue $450M (+36% YoY); FY2025 total revenue guidance $540-560M.
Expects to approach quarterly EPS profitability and positive cash flow in 2H 2025; targets full-year EPS profitability and positive cash flow in 2026.
Plans 2025 NDA for ORLADEYO granules for children <12; two new pipeline programs to enter clinic (BCX17725, avoralstat).
2025 GAAP op ex guidance $485-495M (incl. ~$60M stock comp); non-GAAP op ex $425-435M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.